Targeted therapies: PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations (Q42869821)
Jump to navigation
Jump to search
scientific article published on October 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Targeted therapies: PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations |
scientific article published on October 2010 |
Statements
1 reference
Targeted therapies: PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations (English)
1 reference
Lisa Hutchinson
1 reference
1 October 2010
1 reference
1 reference
7
1 reference
10
1 reference
549
1 reference
1 reference
Identifiers
1 reference
1 reference